Evaluation of quality assessment for CPXV vaccines.

The Ramachandran plot assessment displays (A). For CPVX-V1, 92.4% of the residues are located within favored regions, 6.3% in the allowed region, and 0.6% in the disallowed region. (B) For CPVX-V2, 90.8% of the residues are located within favored region...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Md. Mohaimenul Islam Tareq (21647527) (author)
مؤلفون آخرون:	Sattyajit Biswas (21647530) (author), Farazi Abinash Rahman (21647533) (author), Labib Sharirar Siam (21647536) (author), Sadia Jannat Tauhida (21647539) (author), Shamim Ahmed (207438) (author), Hasan Jafre Shovon (21647542) (author), Mariya Ahmed (21647545) (author), Kazi Afrin Jerin (21647548) (author), Md. Nazmul Hasan (11525006) (author)
منشور في:	2025
الموضوعات:	Biochemistry Medicine Microbiology Genetics Biotechnology Immunology Cancer Infectious Diseases Virology Biological Sciences not elsewhere classified three outer membrane term epitope visibility structural validation enabled quality 3d structures lumpy skin disease linked using aay discover possible targets certain distinctive features proteins &# 8217 xlink "> cpxv protein resolve a22 epitope vaccine constructions namely sheeppox virus developed vaccines might computational cloning analysis 122 cpxv proteins cell epitopes based extracellular proteins cell epitopes scaffold protein protein a35 v5 vaccine potential vaccine work used vipr database varied immunological solid foundation sheeppox ), several investigations results suggest quite safe practical settings physiochemical properties molecular weight molecular modeling molecular dynamics l12 adjuvants kk linkers immunoinformatic methodology huge socio gtpv ), grand average generate multi g activity economic effects docking scores comprehensive immunity cai value amino acids
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

الوصف
الملخص:	<p>The Ramachandran plot assessment displays <b>(A)</b>. For CPVX-V1, 92.4% of the residues are located within favored regions, 6.3% in the allowed region, and 0.6% in the disallowed region. <b>(B)</b> For CPVX-V2, 90.8% of the residues are located within favored regions, 5.3% in the allowed region, and 1.5% in the disallowed region. <b>(C)</b> For CPVX-V5, 90.5% of the residues are located within favored regions, 6.2% in the allowed region, and 0.7% in the disallowed region. <b>(D)</b> For CPVX-V4, 89.7% of the residues are located within favored regions, 7.7% in the allowed region, and 0.7% in the disallowed region. <b>(E)</b> For CPVX-V3, 93.1% of the residues are located within favored regions, 4.6% in the allowed region, and 0.6% in the disallowed region.</p>

Evaluation of quality assessment for CPXV vaccines.

مواد مشابهة